Basilea PharmaceuticaXSWX:BSLN -0.55%59 Net Current Asset Value is CHF7.95 as of Dec. 2025, which is 100% below its 10-year median of 9.11. GuruFocus rates XSWX:BSLN with a GF Score™ of 59/100 and a GF Value™ of CHF57.68 (Fairly Valued). The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, Basilea Pharmaceutica ranks worse than 61.89% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Basilea Pharmaceutica's net current asset value per share for the quarter that ended in Dec. 2025 was CHF7.95.
The historical rank and industry rank for Basilea Pharmaceutica's Net Current Asset Value or its related term are showing as below:
XSWX:BSLN'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.88 Med: 9.11 Max: 11.33
Current: 6.88
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Basilea Pharmaceutica was 11.33. The lowest was 6.88. And the median was 9.11.
XSWX:BSLN's Price-to-Net-Current-Asset-Value is ranked worse than 61.89% of 942
companies
in the Biotechnology industry
Industry Median: 4.9
vs XSWX:BSLN: 6.88
Basilea Pharmaceutica (XSWX:BSLN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Basilea Pharmaceutica Net Current Asset Value Related Terms
Basilea Pharmaceutica Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica Net Current Asset Value Chart
XSWX:BSLN vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of CHF7.95 mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Net Current Asset Value of CHF7.95 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Basilea Pharmaceutica and its competitors. This is 13% below median its historical median of 9.11. Over the past decade, Basilea Pharmaceutica's Net Current Asset Value has ranged from 6.88 to 11.33. According to the industry distribution chart, Basilea Pharmaceutica ranks #583 out of 942 companies in the Biotechnology industry, placing it in the top 61.9%.
Is Basilea Pharmaceutica's Net Current Asset Value too high?
Basilea Pharmaceutica's current Net Current Asset Value of CHF7.95 is 13% below median its 10-year median of 9.11. Over the past 10 years, this metric has ranged from a low of 6.88 to a high of 11.33. Based on the distribution chart, Basilea Pharmaceutica ranks #583 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #583 out of 942 companies for Net Current Asset Value. This places Basilea Pharmaceutica in the lower half of its industry. The industry median Net Current Asset Value is 4.90. Historically, Basilea Pharmaceutica's own Net Current Asset Value has ranged from 6.88 to 11.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.90, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Net Current Asset Value is CHF7.95, which is 13% below median its own 10-year median of 9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.68, compared to a current price of CHF54.70 — trading 5.2% below its estimated fair value. The current Net Current Asset Value is CHF7.95, which is 13% below median its 10-year median of 9.11. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Net Current Asset Value is CHF7.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF54.70 is trading 5.2% below its estimated GF Value™ of CHF57.68.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
Net Current Asset Value: CHF7.95 (13% below median its 10-year median of 9.11)
GF Value™: CHF57.68 vs. price of CHF54.70 (5.2% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score
Get the complete analysis for XSWX:BSLN
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
